Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Go back to Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 215.50 -3.55 (1.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $219.05 | 52 Week High | $333.65 | |||
| Open | $219.05 | 52 Week Low | $223.02 | |||
| Day High | $220.17 | P/E | 27.59 | |||
| Day Low | $215.26 | EPS | $7.81 | |||
| Volume | 2,635,884 | |||||
